Atlas Trials

Grade 3a Follicular Lymphoma

22 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Grade 3a Follicular Lymphoma

RecordFirmDate
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (NCT05169658)University of Washington2022-03-23
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas (NCT04883437)Emory University2021-09-03
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma (NCT04450173)University of California, Davis2021-02-24
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma (NCT04257578)University of Washington2020-12-02
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma (NCT04404088)M.D. Anderson Cancer Center2020-07-16
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT03410901)Ronald Levy2018-04-09
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (NCT03198026)Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University2018-02-20
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (NCT03269669)National Cancer Institute (NCI)2018-01-23
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma (NCT03010358)Alexey Danilov, MD2017-07-17
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02992522)Beth Christian2017-02-21
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02950220)Kami Maddocks2017-01-12
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma (NCT02871219)M.D. Anderson Cancer Center2016-12-06
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma (NCT02927964)Robert Lowsky2016-11-07
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma (NCT02532257)M.D. Anderson Cancer Center2016-04-11
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma (NCT01995669)M.D. Anderson Cancer Center2014-05-27
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (NCT01286272)National Cancer Institute (NCI)2011-04-28

Track Grade 3a Follicular Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.